LUCD - NASDAQ

Lucid Diagnostics Inc.

LUCD·NASDAQ

$1.02

+0.49%

HealthcareMedical - Devices

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$104.35M

EPS-0.6900

P/E Ratio-1.48

Earnings Date08/12/2026

40.45M

Assets

32%

3Y+24.0%

5Y+1743.0%

10Y+227119.0%

29.51M

Total Liabilities

17%

3Y+212.0%

5Y+88.0%

10Y+2631.0%

10.94M

Total Equity

103%

3Y-53.0%

5Y-181.0%

10Y-1129.0%

Lucid Diagnostics Inc. Funding & Solvency Profile

LUCD · NASDAQ

Current Assets

Cash & Cash Equivalents34.70B

Net Receivables643.00K

Inventory353.00M

Other Current Assets-35.02B

Total Current Assets37 M

Non-Current Assets

Property, Plant & Equipment2.62B

Goodwill & Intangible Assets315.00M

Long-Term Investments0.00

Other Non-Current Assets-2.93B

Total Non-Current Assets-312023000

Total Assets

40.45M

Financial Health Analysis

Current Ratio

1.31x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Debt-to-Equity Ratio

2.70x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

9 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

93% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Lucid Diagnostics Inc. Balance Sheet

LUCD • NASDAQ

Lucid Diagnostics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	34.7B	22.4M	18.9M	22.5M	53.7M	111K	156.4K	17.8K
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	118.1K	0.0
Cash & Short-Term Investments	34.7B	22.4M	18.9M	22.5M	53.7M	111K	156.4K	17.8K
Net Receivables	643K	405K	45K	17K	200K	0.0	0.0	0.0
Accounts Receivables	643K	45K	45K	17K	200K	0.0	0.0	0.0
Other Receivables	0.0	360K	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	353M	341K	278K	111K	493K	834K	0.0	0.0
Prepaids	1.8M	2M	873K	1.8M	3M	495K	116.4K	0.0
Other Current Assets	-35B	0.0	2M	0.0	0.0	0.0	118.1K	0.0
Total Current Assets	37.5M	25.1M	22.1M	24.4M	57.3M	1.4M	390.9K	17.8K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.6B	3.7M	2.6M	3.6M	971K	0.0	0.0	0.0
Intangible Assets	315M	736K	1.4M	3.4M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	315M	736K	1.4M	3.4M	0.0	0.0	0.0	0.0
Other Non-Current Assets	-2.9B	1.1M	1.1M	1.1M	725K	755K	643K	0.0
Total Non-Current Assets	3M	5.6M	5.2M	8.2M	1.7M	755K	643K	0.0
Total Assets	40.4M	30.7M	27.3M	32.5M	59M	2.2M	1M	17.8K
LIABILITIES
CURRENT LIABILITIES
Total Payables	970K	1.2M	10.5M	1.1M	3.1M	15.3M	799.1K	497.2K
Accounts Payable	970K	1.2M	1.1M	1.1M	1.5M	2.1M	799.1K	497.2K
Other Payables	0.0	0.0	9.3M	0.0	1.7M	13.3M	0.0	0.0
Accrued Expenses	0.0	1.5M	2.1M	879K	556K	394K	223.7K	0.0
Short Term Debt	893M	18.6M	14M	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	854K	1.1M	962K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	936K	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	-865.4M	1.4M	791K	5.5M	557K	0.0	5.3M	583.3K
Total Current Liabilities	28.6M	23.5M	29.4M	8.4M	4.3M	15.7M	6.3M	1.1M
NON-CURRENT LIABILITIES
Long Term Debt	24.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	927K	1.8M	199K	1M	0.0	0.0	0.0	0.0
Capital Lease Obligations	927K	2.7M	1.3M	2M	0.0	0.0	0.0	0.0
Total Liabilities	29.5M	25.3M	29.6M	9.5M	4.3M	15.7M	6.3M	1.1M
SHAREHOLDERS' EQUITY
Preferred Stock	54.3M	54.4M	18.6M	0.0	0.0	0.0	0.0	0.0
Common Stock	131K	63K	42K	41K	35K	14K	14.1K	10K
Additional Paid-In Capital	230.9M	154.7M	129.8M	121.1M	96.6M	294K	223.1K	0.0
Retained Earnings	-274.3M	-203.8M	-150.7M	-98.1M	-41.9M	-13.8M	-5.5M	-1.1M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.2K
Total Stockholders' Equity	10.9M	5.4M	-2.3M	23M	54.7M	-13.5M	-5.3M	-1.1M
Total Equity	10.9M	5.4M	-2.3M	23M	54.7M	-13.5M	-5.3M	-1.1M
SUMMARY
Total Liabilities & Equity	40.4M	30.7M	27.3M	32.5M	59M	2.2M	1M	17.8K
Total Investments	0.0	0.0	0.0	0.0	0.0	0.0	118.1K	0.0
Total Debt	25.8B	21.3M	15.3M	2M	0.0	0.0	0.0	0.0
Net Debt	-8.9B	-1.1M	-3.6M	-20.5M	-53.7M	-111K	-156.4K	-17.8K
Shares Outstanding	101,893,255	101,893,255	101,893,255	101,893,255	101,893,255	101,893,255	101,893,255	101,893,255

SEC Filings

LUCD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 24, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	March 26, 2026	March 26, 2026		View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
S-3 S-3 N/A	December 05, 2025	December 05, 2025		View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 105 filings

Related Guides

Blog Categories

Continue your LUCD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.